Selpercatinib treatment resulted in superior progression-free survival and treatment failure-free survival as compared with cabozantinib or vandetanib in patients with RET-mutant medullary thyroid cancer. (Funded by Loxo Oncology, a subsidiary of Eli Lilly; LIBRETTO-531 ClinicalTrials.gov number, NCT04211337.).
No takes yet. Share an insight, caveat, or question.
Hadoux et al. (2023) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: